MeSH term
Frequency | Condition_Probility | Aged | 40 | 0.0 |
Humans | 293 | 0.0 |
Risk | 2 | 0.0 |
Time Factors | 13 | 0.0 |
Child, Preschool | 12 | 0.0 |
Family Health | 3 | 0.0 |
Female | 124 | 0.0 |
Glyoxylates/metabolism | 4 | 66.0 |
Infant | 9 | 0.0 |
Male | 122 | 0.0 |
Molecular Sequence Data | 61 | 0.0 |
Oxalates/urine | 2 | 66.0 |
Pedigree | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 152 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 131 | 0.0 |
Amino Acid Sequence | 32 | 0.0 |
Animals | 67 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Mice | 32 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Angiotensinogen/*blood | 2 | 33.0 |
Middle Aged | 84 | 0.0 |
Renin-Angiotensin System/*genetics | 19 | 40.0 |
Angiotensinogen/*genetics/metabolism | 4 | 80.0 |
Base Sequence | 49 | 0.0 |
Comparative Study | 39 | 0.0 |
DNA Primers/chemistry | 5 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Plasmids | 7 | 0.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Rats | 21 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
Transfection | 13 | 0.0 |
Tumor Cells, Cultured | 24 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Species Specificity | 9 | 0.0 |
Structure-Activity Relationship | 9 | 0.0 |
Adult | 85 | 0.0 |
Angiotensinogen/genetics | 9 | 27.0 |
DNA Primers | 12 | 0.0 |
Genotype | 68 | 0.0 |
Nitric-Oxide Synthase/*genetics | 3 | 3.0 |
Peptidyl-Dipeptidase A/genetics | 10 | 12.0 |
Polymorphism, Genetic | 31 | 0.0 |
Receptor, Angiotensin, Type 1/genetics | 3 | 50.0 |
Retrospective Studies | 6 | 0.0 |
Treatment Failure | 2 | 0.0 |
Antineoplastic Agents, Alkylating/*pharmacology | 9 | 23.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Cyclins/biosynthesis | 2 | 2.0 |
DNA-Binding Proteins/biosynthesis | 2 | 2.0 |
Drug Interactions | 4 | 0.0 |
Drug Screening Assays, Antitumor | 3 | 0.0 |
Guanine/*analogs & derivatives/pharmacology | 13 | 41.0 |
O(6)-Methylguanine-DNA Methyltransferase/metabolism | 7 | 50.0 |
Phenotype | 13 | 0.0 |
Protein p53/biosynthesis | 2 | 1.0 |
Carmustine/pharmacology | 5 | 22.0 |
Cell Line | 11 | 0.0 |
DNA Repair | 17 | 2.0 |
O(6)-Methylguanine-DNA Methyltransferase/*genetics/metabolism | 5 | 35.0 |
*Transduction, Genetic | 2 | 2.0 |
Adolescent | 24 | 0.0 |
Angiotensinogen/*genetics | 55 | 61.0 |
Child | 20 | 0.0 |
*Kidney Transplantation | 4 | 0.0 |
Peptidyl-Dipeptidase A/*genetics | 15 | 4.0 |
Receptor, Angiotensin, Type 1 | 8 | 6.0 |
Receptors, Angiotensin/*genetics | 7 | 15.0 |
Gene Expression Regulation | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Gene Expression | 6 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Renin/genetics | 2 | 16.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Sex Factors | 4 | 0.0 |
Alleles | 43 | 0.0 |
Gene Frequency | 34 | 0.0 |
Hypertension/*genetics | 15 | 14.0 |
Angiotensinogen/*metabolism | 2 | 100.0 |
Kidney/*metabolism | 2 | 1.0 |
Case-Control Studies | 21 | 0.0 |
English Abstract | 15 | 0.0 |
Kidney Failure, Chronic/genetics | 2 | 22.0 |
Polymerase Chain Reaction | 40 | 0.0 |
*Polymorphism, Genetic | 39 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Antineoplastic Agents/*therapeutic use | 3 | 0.0 |
Carmustine/*therapeutic use | 3 | 75.0 |
Drug Resistance, Neoplasm | 8 | 1.0 |
*Mutation | 13 | 0.0 |
DNA Mutational Analysis | 10 | 0.0 |
Hyperoxaluria/*genetics | 2 | 40.0 |
Transaminases/*genetics | 5 | 16.0 |
Point Mutation | 13 | 0.0 |
Mutation, Missense | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 9 | 0.0 |
Pregnancy | 9 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Variation (Genetics) | 10 | 0.0 |
Body Mass Index | 6 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Pre-Eclampsia/*genetics | 4 | 21.0 |
Risk Factors | 15 | 0.0 |
Age Factors | 6 | 0.0 |
Disease Progression | 5 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Multigene Family | 2 | 0.0 |
*Phenotype | 3 | 1.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Asian Continental Ancestry Group/*genetics | 5 | 1.0 |
European Continental Ancestry Group/*genetics | 4 | 1.0 |
Evolution, Molecular | 3 | 0.0 |
Exons/genetics | 2 | 0.0 |
Gene Frequency/genetics | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Japan | 7 | 0.0 |
Linkage Disequilibrium/genetics | 2 | 1.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Protein Conformation | 5 | 0.0 |
Aging | 2 | 0.0 |
Codon | 2 | 0.0 |
Cohort Studies | 3 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 2 | 0.0 |
Sex Characteristics | 3 | 0.0 |
Hyperoxaluria, Primary/enzymology/*genetics | 4 | 66.0 |
Mutation | 14 | 0.0 |
COS Cells | 4 | 0.0 |
Cytosol/*enzymology | 2 | 3.0 |
Liver/*enzymology/ultrastructure | 6 | 50.0 |
Mitochondria/*enzymology | 6 | 5.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Subcellular Fractions/enzymology | 4 | 4.0 |
Transaminases/chemistry/genetics/*metabolism | 2 | 100.0 |
Aging/physiology | 2 | 1.0 |
Blood Pressure/*genetics | 10 | 17.0 |
Diastole | 2 | 2.0 |
Haplotypes | 10 | 0.0 |
Methionine | 3 | 7.0 |
Polymorphism, Genetic/*physiology | 2 | 2.0 |
Systole | 2 | 2.0 |
*Alleles | 3 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Exons | 7 | 0.0 |
Heterozygote | 5 | 0.0 |
Kidney/physiopathology | 3 | 5.0 |
Transaminases/*genetics/metabolism | 3 | 50.0 |
*Variation (Genetics) | 11 | 1.0 |
Blood Pressure | 11 | 1.0 |
Cross-Sectional Studies | 5 | 0.0 |
Tissue Donors | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
DNA Adducts | 2 | 2.0 |
Flow Cytometry | 2 | 0.0 |
Homozygote | 8 | 0.0 |
Mice, Knockout | 2 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*metabolism | 3 | 16.0 |
Blood Pressure/drug effects/genetics | 2 | 50.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
Hypertension/*genetics/physiopathology | 6 | 25.0 |
Injections, Intravenous | 3 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Transgenes | 2 | 0.0 |
Drug Administration Schedule | 5 | 0.0 |
Neutropenia/chemically induced | 2 | 5.0 |
Thrombocytopenia/chemically induced | 2 | 10.0 |
Treatment Outcome | 3 | 0.0 |
Evaluation Studies | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 5 | 1.0 |
Aldosterone Synthase/genetics | 2 | 11.0 |
Reference Values | 15 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Logistic Models | 2 | 0.0 |
Odds Ratio | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 7 | 0.0 |
Prevalence | 7 | 0.0 |
Renin-Angiotensin System/genetics | 3 | 13.0 |
Gene Deletion | 4 | 0.0 |
Transplantation, Heterologous | 5 | 0.0 |
DNA/metabolism | 4 | 0.0 |
Hamsters | 9 | 0.0 |
Methylnitronitrosoguanidine/*toxicity | 3 | 60.0 |
DNA/analysis | 2 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Circadian Rhythm | 2 | 0.0 |
Age of Onset | 3 | 0.0 |
Cholesterol/blood | 4 | 0.0 |
Receptor, Angiotensin, Type 2 | 3 | 3.0 |
Receptors, Angiotensin/genetics/metabolism | 2 | 50.0 |
Triglycerides/blood | 3 | 0.0 |
Angiotensinogen/*blood/*genetics | 3 | 100.0 |
*Evolution, Molecular | 2 | 0.0 |
Linkage Disequilibrium | 9 | 1.0 |
Nigeria | 2 | 3.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Amino Acid Substitution | 7 | 0.0 |
European Continental Ancestry Group | 5 | 0.0 |
France | 2 | 0.0 |
Kinetics | 14 | 0.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Protein Transport | 2 | 0.0 |
Restriction Mapping | 5 | 0.0 |
Spectrophotometry | 2 | 1.0 |
Alkylation | 3 | 4.0 |
Binding Sites | 7 | 0.0 |
*DNA Damage | 8 | 1.0 |
*DNA Repair | 18 | 2.0 |
Guanine/*analogs & derivatives/metabolism | 8 | 32.0 |
Hydrogen Bonding | 2 | 1.0 |
Models, Molecular | 2 | 0.0 |
Protein Binding | 5 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
*Liver Transplantation | 5 | 3.0 |
Escherichia coli/*drug effects/genetics | 2 | 33.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics/*physiology | 2 | 33.0 |
O(6)-Methylguanine-DNA Methyltransferase/*analysis | 2 | 50.0 |
Oligonucleotides | 3 | 4.0 |
Sensitivity and Specificity | 6 | 0.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Mitochondria/metabolism | 2 | 0.0 |
Oxalates/*metabolism | 2 | 100.0 |
RNA, Messenger/analysis | 2 | 0.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
Codon/genetics | 3 | 0.0 |
European Continental Ancestry Group/genetics | 5 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*genetics | 2 | 6.0 |
Risk Assessment | 3 | 0.0 |
Blotting, Southern | 6 | 0.0 |
Transaminases/deficiency/*genetics | 3 | 100.0 |
Genetic Predisposition to Disease/epidemiology | 2 | 2.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Alanine/metabolism | 4 | 11.0 |
Biopsy | 5 | 0.0 |
Kidney Transplantation | 3 | 2.0 |
Liver Transplantation | 2 | 3.0 |
Hong Kong/epidemiology | 2 | 7.0 |
Hypertension/ethnology/*genetics | 3 | 25.0 |
Phosphorylation | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Catalysis | 3 | 0.0 |
DNA Damage | 8 | 0.0 |
Substrate Specificity | 7 | 0.0 |
Blood Pressure Monitoring, Ambulatory | 2 | 4.0 |
Receptors, Angiotensin/genetics | 4 | 16.0 |
DNA Adducts/*analysis | 2 | 4.0 |
Guanine/analogs & derivatives/analysis | 2 | 66.0 |
Survival Analysis | 3 | 0.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
Carmustine/*pharmacology | 7 | 36.0 |
Cell Survival/drug effects | 5 | 0.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Enzyme Stability | 2 | 1.0 |
*Gene Therapy | 3 | 0.0 |
Australia | 2 | 1.0 |
Linkage (Genetics) | 4 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 2 | 1.0 |
Diabetic Nephropathies/*genetics | 4 | 16.0 |
Exercise/*physiology | 2 | 0.0 |
Exercise Test | 3 | 1.0 |
Cercopithecus aethiops | 2 | 0.0 |
DNA/chemistry | 2 | 0.0 |
Diabetic Retinopathy/genetics | 2 | 33.0 |
Hemoglobin A, Glycosylated/analysis | 2 | 0.0 |
Cardiovascular Diseases/*genetics | 2 | 10.0 |
DNA Probes | 3 | 0.0 |
Hypertension/blood/*genetics | 2 | 16.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Japan/epidemiology | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 2 | 4.0 |
Drug Synergism | 5 | 0.0 |
Glutathione/metabolism | 2 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
Dimerization | 3 | 0.0 |
Mitochondria/enzymology | 6 | 5.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
CHO Cells | 7 | 0.0 |
DNA Adducts/*metabolism | 3 | 6.0 |
*Mutagenesis | 4 | 6.0 |
O(6)-Methylguanine-DNA Methyltransferase/*biosynthesis/genetics | 2 | 66.0 |
*Point Mutation | 5 | 0.0 |
Mutagenesis | 3 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*antagonists & inhibitors | 3 | 50.0 |
Blood Pressure/genetics | 3 | 8.0 |
Regression Analysis | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Cell Division/drug effects | 7 | 0.0 |
Combined Modality Therapy | 4 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Guanine/*analogs & derivatives/therapeutic use | 4 | 80.0 |
Mice, Nude | 11 | 0.0 |
Neoplasm Transplantation | 8 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Liver/enzymology/*pathology | 2 | 28.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Aldosterone/blood | 2 | 1.0 |
Crosses, Genetic | 2 | 0.0 |
China | 2 | 0.0 |
Alkylating Agents/*toxicity | 2 | 16.0 |
DNA/*drug effects | 4 | 23.0 |
Guanine/analogs & derivatives/metabolism | 4 | 26.0 |
Methylation | 3 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/*physiology | 2 | 66.0 |
DNA, Neoplasm/drug effects | 2 | 6.0 |
Blotting, Northern | 3 | 0.0 |
DNA Repair/*drug effects | 3 | 9.0 |
O(6)-Methylguanine-DNA Methyltransferase/analysis | 2 | 100.0 |
Protein Biosynthesis | 3 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Genetic Screening | 2 | 0.0 |
Hypertension/epidemiology/*genetics | 3 | 15.0 |
Statistics | 2 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 3 | 6.0 |
Leukocytes/metabolism | 3 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Neoplasms/*drug therapy | 2 | 1.0 |
Antineoplastic Agents, Alkylating/*therapeutic use | 2 | 11.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Transaminases/analysis | 2 | 66.0 |
Alanine/genetics | 2 | 1.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Threonine/genetics | 3 | 4.0 |
*Genes, ras | 2 | 0.0 |
Glycine/genetics | 4 | 4.0 |
Hydrolysis | 2 | 0.0 |
Swine | 2 | 0.0 |
Polymorphism, Genetic/genetics | 5 | 0.0 |
Hyperoxaluria, Primary/*diagnosis/enzymology/genetics | 2 | 100.0 |
Genes, Recessive | 2 | 0.0 |
Microbodies/enzymology | 10 | 66.0 |
Mitochondria, Liver/enzymology | 3 | 12.0 |
Half-Life | 2 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Cell Compartmentation | 3 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Guinea Pigs | 2 | 0.0 |
Escherichia coli/genetics | 4 | 0.0 |
Europe | 2 | 0.0 |
Family | 2 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Hypertension/blood/*genetics/physiopathology | 2 | 40.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Hypertension/*genetics/*physiopathology | 2 | 40.0 |
Hyperoxaluria, Primary/*genetics | 2 | 100.0 |
Liver/enzymology | 7 | 1.0 |
*Kidney Transplantation/physiology | 2 | 28.0 |
Transplantation, Homologous | 2 | 0.0 |
Liver/metabolism | 4 | 0.0 |
Utah | 2 | 7.0 |
Alanine Transaminase/*genetics | 4 | 21.0 |
*Transaminases | 23 | 82.0 |
Circular Dichroism | 2 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase | 52 | 30.0 |
In Vitro | 3 | 0.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Guanine/*analogs & derivatives/analysis | 2 | 40.0 |
Methyltransferases/*metabolism | 12 | 17.0 |
Angiotensinogen/blood/*genetics | 6 | 100.0 |
Alanine Transaminase/*metabolism | 5 | 62.0 |
Biological Transport | 2 | 0.0 |
Diet | 2 | 0.0 |
Microbodies/*enzymology | 5 | 35.0 |
DNA Repair/drug effects | 3 | 10.0 |
Lymphocytes/enzymology | 3 | 3.0 |
Alkylating Agents/*pharmacology | 2 | 10.0 |
Guanine/analogs & derivatives/pharmacology | 2 | 15.0 |
Methylnitronitrosoguanidine/pharmacology | 3 | 12.0 |
Diabetic Nephropathies/*genetics/physiopathology | 2 | 50.0 |
Prospective Studies | 2 | 0.0 |
Renin-Angiotensin System/*genetics/physiology | 2 | 22.0 |
Dacarbazine/*analogs & derivatives/therapeutic use | 2 | 66.0 |
Ethylnitrosourea/*toxicity | 3 | 42.0 |
Mutation/*drug effects | 2 | 11.0 |
DNA/*metabolism | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Dacarbazine/*analogs & derivatives/pharmacology | 2 | 18.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Methyltransferases/*antagonists & inhibitors | 5 | 38.0 |
Arginine/genetics | 2 | 1.0 |
Hyperoxaluria, Primary/*enzymology | 3 | 100.0 |
Point Mutation/physiology | 2 | 12.0 |
Alanine Transaminase/genetics/*metabolism | 2 | 100.0 |
Immunohistochemistry | 4 | 0.0 |
Gene Therapy | 2 | 0.0 |
Methyltransferases/metabolism | 6 | 19.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Rabbits | 3 | 0.0 |
Drug Resistance | 5 | 0.0 |
Liver/*enzymology | 6 | 1.0 |
Hyperoxaluria/*diagnosis | 2 | 100.0 |
Cattle | 2 | 0.0 |
Cell Death/drug effects | 2 | 1.0 |
Drug Therapy, Combination | 2 | 0.0 |
Hyperoxaluria/*enzymology | 4 | 100.0 |
Autoradiography | 2 | 0.0 |
*Escherichia coli Proteins | 2 | 0.0 |
Alanine/*metabolism | 2 | 33.0 |
Renin/blood | 2 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
DNA/genetics | 4 | 0.0 |
DNA Replication | 2 | 0.0 |
Methyltransferases/physiology | 2 | 66.0 |
DNA | 3 | 0.0 |
*Introns | 2 | 0.0 |
Methylnitronitrosoguanidine/toxicity | 2 | 20.0 |
Immunoblotting | 2 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Liver/enzymology/ultrastructure | 2 | 66.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Methyltransferases/*analysis | 4 | 40.0 |
Hyperoxaluria, Primary/*enzymology/*genetics | 2 | 100.0 |
Microbodies/*enzymology/ultrastructure | 2 | 50.0 |
Mitochondria, Liver/*enzymology/ultrastructure | 2 | 50.0 |
Evolution | 3 | 0.0 |
Methyltransferases/antagonists & inhibitors/*metabolism | 2 | 22.0 |
Hybrid Cells | 2 | 0.0 |
Phosphorus Radioisotopes | 2 | 3.0 |
Cell Line, Transformed | 2 | 0.0 |
Alanine Transaminase/*genetics/metabolism | 3 | 75.0 |
Genes, Structural | 2 | 0.0 |
Hyperoxaluria, Primary/*enzymology/genetics | 2 | 100.0 |
Mutation/genetics | 2 | 0.0 |
Chronic Disease | 3 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Hyperoxaluria/enzymology/*genetics | 2 | 100.0 |
Mitochondria, Liver/*enzymology | 2 | 7.0 |
Cell Transformation, Viral | 2 | 0.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use | 2 | 0.0 |
Introns | 2 | 0.0 |
Lymphocytes/*enzymology | 3 | 4.0 |
Microscopy, Electron | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Prognosis | 3 | 0.0 |
Methionine/genetics | 2 | 4.0 |
Kidney Calculi/*enzymology/*genetics | 2 | 100.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
